Related Experiment Videos
[Cefoperazone in the treatment of infections in newborn infants]
Insights
Cefoperazone monotherapy effectively treated 78.1% of infected neonates and premature infants. This antibiotic showed no adverse reactions, suggesting its value for infant infections.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Neonatal and infant infections pose significant risks.
- Limited treatment options historically led to higher mortality rates.
- Third-generation cephalosporins offer potential for improved outcomes.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of cefoperazone monotherapy in neonates and premature infants.
- To assess the recovery rates and adverse events associated with cefoperazone treatment.
- To compare outcomes with historical mortality data.
Main Methods:
- A clinical evaluation of cefoperazone (Cefobid-Pfizer) monotherapy.
- Administered to 32 infected neonates and premature infants.
- Outcomes monitored for recovery, treatment modifications, and adverse reactions.
Main Results:
- Complete recovery was achieved in 78.1% (25/32) of infants.
- Generalized infections showed a 76.5% recovery rate.
- No adverse reactions or deaths necessitated drug withdrawal; 21.9% required treatment changes.
Conclusions:
- Cefoperazone monotherapy demonstrates high efficacy and a favorable safety profile in treating neonatal and infant infections.
- The results suggest cefoperazone is a valuable therapeutic option, potentially reducing historical mortality rates.
- Widespread adoption of cefoperazone monotherapy in neonates is recommended.
Abstract:
The authors evaluated clinically cefoperazone (Cefobid-Pfizer)--an antibiotic of the III generation of cephalosporins--administering it in the form of monotherapy to 32 infected neonates and premature babies. A complete recovery was achieved im 25 neonates, i.e. 78.1%, out of which 76.5% were generalized infections. The result of therapy was doubtful in the remaining 7 babies (21.9%). The drug was changed or the second antibiotic added. No decidedly unfavourable results (deaths) or adverse reactions necessitating withdrawal of the drug were observed. The authors compare this favourable results with the mortality rate of neonates prior to the introduction of the II and III generation cephalosporins. It was about 14%, then. Therefore, both +antibiotic monotherapy and cefoperazone enabling its use are worth wide popularization in neonates and small babies.